C3 and paroxysmal nocturnal hemoglobinuria: APL-2 (pegcetacoplan) is a compstatin derivative that prevents C3 activation and has recently been approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) [167].